Nxera Pharma Co (FRA:JSS) Cyclically Adjusted Revenue per Share: €0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:JSS Nxera Pharma Co Ltd FRA:JSS
74 GF Score
Price €5.85
GF Value €4.52
! 9 Warning Signs
View Full Analysis

What is Nxera Pharma Co Cyclically Adjusted Revenue per Share?

Nxera Pharma Co FRA:JSS 74 Cyclically Adjusted Revenue per Share is €0.00 as of Jun. 2026. GuruFocus rates FRA:JSS with a GF Score™ of 74/100 and a GF Value™ of €4.52. The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Nxera Pharma Co's adjusted revenue per share for the three months ended in Jun. 2026 was €0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Nxera Pharma Co's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 16.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Nxera Pharma Co was 16.90% per year. The lowest was 14.40% per year. And the median was 15.70% per year.

As of today (2026-08-27), Nxera Pharma Co's current stock price is €5.85. Nxera Pharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €0.00. Nxera Pharma Co's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nxera Pharma Co was 42.01. The lowest was 3.75. And the median was 15.45.


Nxera Pharma Co  (FRA:JSS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nxera Pharma Co was 42.01. The lowest was 3.75. And the median was 15.45.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Nxera Pharma Co Cyclically Adjusted Revenue per Share Related Terms


Nxera Pharma Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Nxera Pharma Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nxera Pharma Co Cyclically Adjusted Revenue per Share Chart

Nxera Pharma Co Annual Data
Trend Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 0.94 0.94 1.10 1.08

Nxera Pharma Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.15 1.14 1.08 1.11 0.00

FRA:JSS vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Nxera Pharma Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Cyclically Adjusted PS Ratio falls into.


FRA:JSS
74GF Score
Nxera Pharma Co Ltd FRA:JSS
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nxera Pharma Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nxera Pharma Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/113.6000*113.6000
=0.000

Current CPI (Jun. 2026) = 113.6000.

Nxera Pharma Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.098 98.000 0.114
201612 0.147 98.400 0.170
201703 0.228 98.100 0.264
201706 0.329 98.500 0.379
201709 0.282 98.800 0.324
201712 0.106 99.400 0.121
201803 0.065 99.200 0.074
201806 0.085 99.200 0.097
201809 0.097 99.900 0.110
201812 0.110 99.700 0.125
201903 0.326 99.700 0.371
201906 0.206 99.800 0.234
201909 0.294 100.100 0.334
201912 0.207 100.500 0.234
202003 0.121 100.300 0.137
202006 0.145 99.900 0.165
202009 0.189 99.900 0.215
202012 0.464 99.300 0.531
202103 0.116 99.900 0.132
202106 0.178 99.500 0.203
202109 0.044 100.100 0.050
202112 1.260 100.100 1.430
202203 0.105 101.100 0.118
202206 0.116 101.800 0.129
202209 0.527 103.100 0.581
202212 0.569 104.100 0.621
202303 0.080 104.400 0.087
202306 0.096 105.200 0.104
202309 0.256 106.200 0.274
202312 0.555 106.800 0.590
202403 0.317 107.200 0.336
202406 0.532 108.200 0.559
202409 0.651 108.900 0.679
202412 0.474 110.700 0.486
202503 0.458 111.100 0.468
202506 0.563 111.700 0.573
202509 0.431 112.000 0.437
202512 0.471 113.000 0.474
202603 0.403 112.700 0.406
202606 0.000 113.600 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.00 mean?
Nxera Pharma Co (FRA:JSS) has a Cyclically Adjusted Revenue per Share of €0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nxera Pharma Co and its competitors.
Is Nxera Pharma Co's Cyclically Adjusted Revenue per Share too high?
Nxera Pharma Co's current Cyclically Adjusted Revenue per Share is €0.00. Overall, Nxera Pharma Co has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Nxera Pharma Co's Cyclically Adjusted Revenue per Share of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nxera Pharma Co and its competitors. Nxera Pharma Co's current Cyclically Adjusted Revenue per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Nxera Pharma Co (FRA:JSS) has a current Cyclically Adjusted Revenue per Share of €0.00. The stock's GF Value™ is €4.52, compared to a current price of €5.85 — trading 29.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.00. Nxera Pharma Co's overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Nxera Pharma Co (FRA:JSS), the current Cyclically Adjusted Revenue per Share is €0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nxera Pharma Co (FRA:JSS) Overvalued in 2026?

Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be overvalued. The current stock price of €5.85 is trading 29.4% above its estimated GF Value™ of €4.52.

Key valuation signals for FRA:JSS:

  • Cyclically Adjusted Revenue per Share: €0.00
  • GF Value™: €4.52 vs. price of €5.85 (29.4% above fair value)
  • GF Score™: 74/100 with 9 warning signs

No single metric tells the full story. See the FRA:JSS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nxera Pharma Co Business Description

Other Exchanges SOLTF:USA4565:Japan
Address Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
74GF Score

Get the complete analysis for FRA:JSS

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.85
Price
€4.52
GF Value